Legend Biotech Corporation (LEGN)
| Previous Close | 40.95 |
| Open | 40.61 |
| Bid | 39.29 x 100 |
| Ask | 39.49 x 100 |
| Day's Range | 38.81 - 40.84 |
| 52 Week Range | 38.60 - 70.13 |
| Volume | |
| Avg. Volume | 1,072,975 |
| Market Cap | 7.271B |
| Beta (5Y Monthly) | 0.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.54 |
| Earnings Date | Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.14 |
GlobeNewswireLegend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as
- GlobeNewswire
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma MRD data to be featured in oral presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting SOMERSET, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present new data on minimal residua
